First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
暂无分享,去创建一个
Y. Doki | M. Okada | R. Ishihara | S. Motoyama | Ken Kato | Y. Matsumura | T. Ogata | T. Kojima | Y. Kitagawa | H. Kawakami | Y. Kubota | Masaki Ueno | C. Amaya-Chanaga | Tian Chen | Yasuhiro Shirakawa
[1] Qi Li,et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. , 2022, Cancer cell.
[2] J. Ajani,et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.
[3] Jinchul Kim,et al. Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis , 2022, Journal of Cancer.
[4] R. Ishihara,et al. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181 , 2021, Esophagus.
[5] Ying Cheng,et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. , 2021, JAMA.
[6] Y. Wang,et al. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study , 2021, Annals of Oncology.
[7] Sung-Bae Kim,et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.
[8] Y. Doki,et al. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3) , 2020, Esophagus.
[9] T. Akimoto,et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer , 2020, ESMO open.
[10] J. Ferlay,et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018 , 2020, Gut.
[11] K. Muro,et al. Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer , 2020, AntiCancer Research.
[12] Lei Dong,et al. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis , 2020, World journal of surgical oncology.
[13] L. Urban,et al. Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817 , 2019 .
[14] R. Motzer,et al. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up , 2019, Japanese journal of clinical oncology.
[15] C. Porta,et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[16] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[17] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[18] Jun Yu Li,et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Masahiro Yoshida,et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 , 2018, Esophagus.
[20] A. Costantini,et al. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Ken Kato,et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma , 2018, International Journal of Clinical Oncology.